A recent CNN Health article discussed the FDA’s approval of Biogen’s experimental drug for early phases of Alzheimer’s disease. The drug, aducanumab, was developed to treat patients with mild cognitive impairment and slow the progression of the neurodegenerative disease, and not just the symptoms. However, an FDA advisory committee determined last year that there wasn’t enough support that the treatment is actually effective.
FDA Approves Controversial New Alzheimer’s Drug
Aduhelm received “accelerated approval” despite differing perspectives from the expert community.
Jun 10, 2021
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
